-
Mashup Score: 25Genentech: Press Releases | Thursday, Sep 12, 2024 - 4 month(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 2Genentech: Press Releases | Thursday, Jul 4, 2024 - 6 month(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
ICYMI: @US_FDA approved the prefilled syringe version of our bispecific treatment for three retinal conditions that cause blindness. Read more: https://t.co/hFh4Cqd9Fe
-
-
Mashup Score: 13Genentech: Press Releases | Saturday, Jun 15, 2024 - 7 month(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: Today at #EHA2024, we’re presenting Phase III results of our CD20xCD3 bispecific antibody in combination with chemotherapy for people living with relapsed or refractory diffuse large B-cell #lymphoma, or #DLBCL. Learn more: https://t.co/mG904VVvKY
-
-
Mashup Score: 10Genentech: Press Releases | Friday, Jun 7, 2024 - 7 month(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: During the Cure SMA Research & Clinical Care Meeting, we presented five-year data evaluating our medicine for spinal muscular atrophy (#SMA) in children with Type 1 SMA. Learn more: https://t.co/D56dOGIkYv
-
-
Mashup Score: 5Genentech: Press Releases | Tuesday, May 28, 2024 - 7 month(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: Our investigational treatment regimen for people with PIK3CA-mutated HR+/HER2- locally advanced or metastatic #breastcancer was granted Priority Review by the @US_FDA. Learn more: https://t.co/fnbigxG4JM
-
-
Mashup Score: 82Genentech: Press Releases | Sunday, Apr 14, 2024 - 8 month(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: Today we announced our CD20xCD3 bispecific antibody in combination with chemotherapy met its primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell #lymphoma, or #DLBCL. Learn more: https://t.co/IFU1bSUbev
-
-
Mashup Score: 54Genentech: Press Releases | Wednesday, May 15, 2024 - 8 month(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: Today we announced positive Phase Ib results for our dual GLP-1/GIP receptor agonist CT-388 in people with #obesity. Learn more: https://t.co/0Rg2XuOL0w
-
-
Mashup Score: 32Genentech: Press Releases | Thursday, Apr 18, 2024 - 9 month(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: The @US_FDA approved our #targetedtherapy as the first adjuvant treatment for certain people with ALK+ early-stage #NSCLC. Learn more: https://t.co/VESgGUcP6s
-
-
Mashup Score: 32Genentech: Press Releases | Thursday, Apr 18, 2024 - 9 month(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: The @US_FDA approved our #targetedtherapy as the first adjuvant treatment for certain people with ALK+ early-stage #NSCLC. Learn more: https://t.co/VESgGUcP6s
-
-
Mashup Score: 32Genentech: Press Releases | Thursday, Apr 18, 2024 - 9 month(s) ago
Discover the latest news about our company, our products, our policies, and our people.
Source: www.gene.comCategories: General Medicine News, PayerTweet-
#Breaking: The @US_FDA approved our #targetedtherapy as the first adjuvant treatment for certain people with ALK+ early-stage #NSCLC. Learn more: https://t.co/VESgGUcP6s
-
#Breaking: Our #immunotherapy is now the first FDA-approved subcutaneous PD-(L)1 inhibitor available to cancer patients in the US. Learn more: https://t.co/fn5fC6DzAA https://t.co/5PZNjUFn9a